---
id: INS-260626-16C8
domain: health
topic: biotechnology
title: 'Clinical AI value must be proven on patient outcomes, not simulated reasoning'
actionability: reference
confidence: high
shelf_life: evergreen
status: active
tags:
  - clinical-ai
  - evidence-quality
  - healthcare
  - randomized-trials
  - evaluation
sources:
  - type: blog
    title: >-
      AI support tool improved clinician decisions in real-world primary care
      trial
    url: 'https://www.eurekalert.org/news-releases/1133583'
date_extracted: '2026-06-26'
last_accessed: null
access_count: 0
indexed: true
embedded: true
embedding_model: "nomic-embed-text"
resolutions:
  one_line: >-
    Real-world clinical AI requires patient-outcome trials because improved
    reasoning proxies may not translate into measurable patient benefit.
  standard: >-
    The AI Consult trial attacked a core bottleneck in healthcare AI: most
    systems are validated on clinician performance, retrospective charts, or
    simulated cases rather than prospective patient outcomes. By randomizing
    clinical officers across 16 Kenyan primary care facilities and tracking
    14-day treatment failure in more than 9,600 patients, the study shifted the
    evidence standard from model competence to field impact.


    The durable lesson is that proxy improvements are not enough in domains
    where deployment risk is borne by humans. Even when an LLM improves
    documentation and treatment planning, the clinically relevant question is
    whether that changes downstream outcomes without introducing harm. Agent and
    eval builders should treat this as a warning against over-claiming from
    offline evals: deployment-grade evidence must measure the target system's
    real externality, not only the AI-visible intermediate task.
stance: >-
  Clinical AI systems should be judged by patient-level outcomes and safety
  signals rather than benchmark or simulated-case performance once they enter
  real care workflows.
---
The AI Consult trial attacked a core bottleneck in healthcare AI: most systems are validated on clinician performance, retrospective charts, or simulated cases rather than prospective patient outcomes. By randomizing clinical officers across 16 Kenyan primary care facilities and tracking 14-day treatment failure in more than 9,600 patients, the study shifted the evidence standard from model competence to field impact.

The durable lesson is that proxy improvements are not enough in domains where deployment risk is borne by humans. Even when an LLM improves documentation and treatment planning, the clinically relevant question is whether that changes downstream outcomes without introducing harm. Agent and eval builders should treat this as a warning against over-claiming from offline evals: deployment-grade evidence must measure the target system's real externality, not only the AI-visible intermediate task.
